Prof. Dai-Ming Fan is a foreign academician in the Institute of Medicine of the National Academies. Also, he is the academician and vice president of the Chinese Academy of Engineering, president of the Fourth Military Medical University, chief physician, a gastroenterology expert in China, director of the State Key Laboratory of Tumor Biology, an invited professor of the cheung kong scholars programme, and a chief scientist of the National Basic Research Program (973 Program). National High Technology Research and Development Program (863 Program), National Programs for Science and Technology Development, Key New Drug Creation and Development Program, Key Program of the National Natural Science Foundation, etc. Prof. Dai-Ming Fan has long been engaged in both the clinical and basic research of digestive diseases and malignant tumor, undertaking sever Groups assigned by the Natural Science Foundation of China.
Gastroenterology; tumor biology
Academician Yan Sun is an academician of the Chinese Engineering Academy, and one of the founders of Chinese internal medicine tumor. Also, he is the honorary dean of Guangzhou NanYang Tumor Hospital, the specialist of International Famous Clinical Oncology Internal Medicine, professor and doctoral tutor of Chinese Academy of Medical Sciences Cancer Hospital, the director of the National Antitumor Drug Clinical Trial Research Center, vice President of China Cancer Research Foundation, vice President of Asia Clinical Oncology Society, committee of the International Union of Cancer (UICC) Academic Affairs, committee of the World Health Organization Cancer Expert Advisory, and the general counsel of Global Cancer Express.
Dr. Miele completed his medical training in Italy and his graduate training at the Max-Planck Institute for Molecular Genetics in Berlin. He then completed a fellowship in Human Genetics at the NIH (NICHD). There, he developed: 1) pharmacologically active peptides from human uteroglobin/CC10; 2) novel expression vectors to produce native, clinical-grade disulfide-bonded human proteins and 3) an early version of PCR-ELISA to quantify normal and mutant DNA in patient blood. In 1994, he moved to FDA/CBER as a senior investigator in the Division of Monoclonal Antibodies and member of the Division of Clinical Trials Design and Analysis. He was eventually promoted Acting Chief, Laboratory of Cell Biology. Dr. Miele co-authored the 1997 Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products. At CBER, in 1994, he began working on the then recently discovered human Notch genes. Notch pathway genes control cell fate determination during normal development and adult life, and have major roles in tumor biology, angiogenesis and the immune system. In 1998, Dr. Miele moved to Loyola University's Cardinal Bernardin Cancer Center, where he discovered the anti-apoptotic activity of Notch1 in leukemia cells. At the same time, he created and oversaw a Molecular Pathology Core. In 2001, Dr. Miele moved to the University of Illinois at Chicago, as Program Director in the Cancer Center and Associate Professor of Biopharmaceutical Sciences. At UIC, Dr. Miele determined that Notch1 is necessary for Ras-induced transformation of human cells and is expressed in breast cancer. In 2005, he returned to Loyola, as a Full Professor, Breast Cancer Program Director and eventually, Associate Cancer Center Director for Translational Sciences. In 2009, Dr. Miele was named Director of the UMMC Cancer Institute and Ergon Professor of Medicine. He held that post until his move to LSUHSC. Dr. Miele’s work is devoted to: 1) studies of cancer stem cell-regulatory genes such as Notch, and identification of genetic circuitry mediating Notch signals in human tumors; 2) Correlation between GWAS data and transcriptome for cancer-associated genes; 3) Mechanism-based early clinical trials using genomic biomarkers as correlative endpoints and/or stratification variables. Dr. Miele has authored 195 publications in biomedical journals to date. He has served or serves on numerous grant review panels for NIH, NCI, NCATS, the DOD and foreign research funding agencies from Canada, the UK, Spain, Italy, The Netherlands and Singapore. He serves as Editor or Associate Editor of a number of biomedical journals, and has served as an advisor to several pharmaceutical and biotechnology companies.
Immunology; molecular medicine; breast cancer; prostate tumor
Dr. Chen has recieved his MS degree in Biochemical Pharmacology/Toxicology from Sun YatSen University China,MD degree from Guangdong Medical and Pharmaceutical College China, Ph D degree in Cancer Pharmacology from Kagoshima University School of Medicine Japan, Postdoctoral training at Kagoshima University Japan, another Postdoctoral training in the Department of Medical Oncology Fox Chase Cancer Center Philadelphia. He started his professional career as Assistant professor at St. John's University in 2004. After that he worked as Associate professor at St.John's University in 2008.His research effortsare enclosed in Cancer Pharmacology and Experimental Therapeutics especially focusing on cellular mechanisms of multidrug resistance MDR. He has been involved in the research of most of the multidrug resistance proteins MRPs and have published ~60 publications in peerreviewed Journals for the last 10 years. He teaches Biochemistry Pharmacology Oncology at St John's University. He is a reviewer of 33 journals including International Journals and an editorial board member of 10 journals.
Molecular and cellular pharmacology of anticancer drugs, such as drug resistance mechanisms and reversal of resistance study and new drug development; breast cancer; oral cancer
Dr. Datta is Professor and Director of Research in the Division of Hematology/Oncology. He is also leader of the Colon and Lung Cancer Basic Research Program. He serves as Research Scientist at the Veterans Affairs Medical Center. Dr. Datta majors in the mechanism of TGF-β signaling in Colorectal Cancer and Lung Cancer. Dr. Datta published his research results in some famous international journals such as Gastroenterology, Cancer Research, JBC and he also serves as the Reviewer for Cancer Research, Clinical Cancer Research, Neoplasia.
GI; liver cancers
Dr. Farassati was trained as a Molecular Oncologist and Cancer Gene Therapist at the University of Calgary, Harvard Medical School and Mayo Clinic. His Research is mainly focused on understanding the features of pro-oncogenic cell signaling events in cancer cells and utilizing this knowledge to design gene and drug therapy strategies to target them. He currently directs the Molecular Medicine Laboratory at the University of Kansas Medical Center (Kansas City, KS, USA) where a group of clinicians and scientists study a range of human malignancies including brain tumors in adults and children under his leadership. Concepts pursued by this team to target brain tumors include gene therapy strategies using oncolytic viruses, identification and intervention with novel cell signaling pathways involved in generation of brain malignancies and designing gene therapy strategies to target cancer stem cells.
Pancreatic cancer; neuro-oncology; intervention with Ras signaling pathway; gliomas, medulloblastomas and malignant peripheral nerve sheath tumors and generating translational tools to target this pathway
Umberto Galderisi is Professor of Molecular Biology at the School of Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, and Adjunct Professor, Sbarro Inst. for Cancer Research and Mol. Medicine, Temple Univ, Philadelphia, USA. He obtained his master degree in Biological Sciences, summa cum laude, University of Naples, Italy in 1987, he did his PhD in Department of Genetics, General and Molecular Biology, University of Naples, Italy in 1992. The major research interests include stem cells, cancer stem cells, senescence, apoptosis, cell cycle, oncogenes and oncosuppressors.
Stem cells, cancer stem cells, senescence, apoptosis, cell cycle, oncogenes, oncosuppressors
National Association of Italian Biologist.
ISSCR (International Society for Stem Cell Researches).
International Society for Cellular Therapy (ISCT).
ECSA (European Cellular Senescence Association).
Founder and President of Stem Cell Research Italy, scientific association of researchers involved in stem cell studies (www.stemcellitaly.org).
Dr. Gopal Kundu has obtained his Ph.D. in chemistry from Bose Institute, Kolkata, India (1989). He did his post-doctoral research work at the Cleveland Clinic Foundation, University of Colorado, University of Wyoming, and the National Institutes of Health from 1989 to 1998. He has performed work in the area of cardiovascular biology, inflammation and immunomodulation during that period. In 1998, he joined as Scientist-D at National Centre for Cell Science (NCCS), India and at present he is Scientist-G. His area of research at NCCS is tumor biology, regulation of gene expression, cell signaling, cancer stem cells, angiogenesis, cancer therapeutics, biomarker studies and nanomedicine. He has received several awards including Fellows Award for Research Excellence from NIH, USA; National Bioscience Award, Govt. of India; Shanti Swarup Bhatnagar Prize, Govt. of India; International Award in Oncology, Greece; International Young Investigator Award, USA and 7th National Grassroots Innovation Award, Rashtrapati Bhavan, India. He is Fellow of National Academy of Sciences and Indian Academy of Sciences. He has published 74 papers including Nature Medicine, Science, PNAS, Cancer Research, JBC, TCB, Oncogene, Nanomedicine etc and one US patent. He serves as Editorial Board Member of Current Molecular Medicine, Molecular Medicine Reports, The Open Cancer Journal and American Journal of Cancer Research.
Tumor biology; regulation of gene expression; angiogenesis; cancer stem cells; chemical biology and nanotechnology
Dr. Jian Jian Li received undergraduate training at Xian Medical College and obtained the Mater of Medicine degree 1984 at Fourth Military Medicine University, China. Awarded the UICC (International Union Against Cancer) Fellowship in 1988, he worked as Research Fellow in the Department of Radiation Oncology, University of California San Francisco (1988-90), earned his Ph.D. of Radiation Biology in 1994 at University of Iowa before training as Postdoctoral Fellow at National Cancer Institute, National Institutes of Health (1995-98). He started faculty position (Assistant, Associate Professor) at City of Hope Medical Center (1999-04), and Associate and Full Professor at Purdue University (2004-09). Since 2009 he is serving as Full Professor and Director of Translational Research at the Department of Radiation Oncology, University of California Davis School of Medicine and NCI-Designated Comprehensive Cancer Center. Dr. Li’s research is to reveal the mechanisms causing cancer therapy-resistance due to reprograming mitochondrial metabolism and repopulation of cancer stem cells. He has published >100 papers including Dev. Cell, Cancer Research, Clin. Cancer Research, Oncogene, JBC, Mol. Cancer Research, and was/is Associate Editor/Editorial Board Member for Cell Research, BMC Physics, Int. J. Radiation Biology, J. Cancer Metastasis and Treatment, PLOS ONE, Radiation Research, and member in many grant review panels including National Institutes of Health, Cancer Research United Kingdom, National Natural Science Foundation of China, Technology and Research (A*Star) of Singapore, and a reviewer for many scientific journals.
Cancer radioresistance, mitochondrial function, metabolism, cancer stem cells, therapeutic targets.
Yin-Yuan Mo is Professor in the Department of Pharmacology/Toxicology, Cancer Institute, at University of Mississippi Medical Center. His research interests are epigenetic regulation of genes involved in tumorigenesis and chemoresistance, cancer susceptibility due to alterations of microRNA expression, and lncRNA-mediated gene expression in cancer.
Epigenetic regulation of genes involved in tumorigenesis and chemoresistance; cancer susceptibility due to alterations of microrna expression; long non-coding rna-mediated gene expression in cancer
Dr. Nicolini graduated (summa cum laude) at School of Medicine, University of Pisa in 1974. He received postgraduate diplomas at University of Pisa in Internal Medicine (1980), Pneumology (1984), and Nuclear Medicine (1986). His research interests include breast and gastrointestinal cancer and their metastases, tumour markers, post-operative follow-up, physiopathology, immunology and immunotherapy of cancer, and thyroid tumours.
Malignant solid tumours; breast cancer; colorectal cancer and their metastases; tumour markers; post-operative follow-up; physiopathology; immunology and immunotherapy of cancer; thyroid tumours
Professor Godefridus (Frits) J. Peters is head of the Laboratory Medical Oncology of the VU University Medical Center (VUmc) in Amsterdam (the Netherlands). He did his Ph.D. at the University of Mijmegen and was appointed in 1998 as head of the division of Pharmacology and deputy-head of the laboratory and in 2003 as head of the Laboratory of the Department of Medical Oncology and as full professor. The major research interests include all aspects of pharmacology of anticancer agents, with emphasis on antimetabolites, antifolates, platinum analogs, taxanes and anti-signalling agents, so-called targeted-agents. The main focus is on cancers derived from epithelial cells, such as colon and lung cancer. His group was one of the first to describe the prognostic role of thymidylate synthase in the antitumor activity of 5-fluorouracil against colon cancer, and used this principle to select treatment showing that selection of patients based on gene expression increased response rate 2-fold. At this moment the emphasis is on the role of genetic polymorphisms in drug metabolism and on all types of drug-resistance, including the role of various multidrug-resistance associated proteins (MRPs) and breast cancer associated resistance protein (BCRP) in resistance to targeted agents, and their role in the uptake of orally administered drugs from the gut. Prof. Peters has authored/co-authored >410 refereed papers and 165 papers/chapters in books and congress proceedings, He is/was member of >25 editorial boards, was founder and first president of the Purine and Pyrimidine Society, and was chair of the EORTC-Pharmacology and Molecular Mechanisms Group.
Pharmacology of anticancer drugs; treatment of pancreatic and lung cancer; developments in metabolic disorders; colorectal cancer; esophageal cancer; pediatric acute myeloid leukemia
Masayuki Watanabe, Japanese pediatrician. Diplomate Ministry Health Labor Welfare Japan, 1995. Member of Japan Society Perinatal Neonatal Medicine, Japanese Society Pediatrics Cardiology Cardiac Surgery, Japanese Society Pediatrics Allergy Clinical Immunology, Japan Pediatrics Society.
Gastroenterological cancer; gastric cancer; esophageal cancer; liver metastasis; colon cancer
Yaguang Xi serves as an Professor of LSU Health Sciences Center New Orleans, USA. In 2003, Dr. Xi earned his Ph.D. degree in cancer biology from the Peking University after he accomplished the medical training. His expertise covers molecular biology, cell biology, genomics, genetics, oncology, and bioinformatics. Currently, Dr. Xi focuses on characterizing micro-RNA biomarkers and validating their important roles in cancer development, tumor metastasis, chemotherapy, and prevention.Yaguang Xi is currently working in Oncologic Sciences, Mitchell Cancer Institute at the University of South Alabama. He has got many memberships in professional asociations like American Association for Cancer Research, American Society of Clinical Oncology, International Honor Society Beta Gamma Sigma. Also he has won many awards for his research works and for his teaching experience.His major projects are holding the grants from NIH.
Colorectal cancer; breast cancer metastasis
Prasad S Adusumilli has completed his M.B.B.S. at the age of 22 years from Guntur Medical College and postdoctoral studies from AIIMS, New Delhi, Southampton University, UK and from Memorial Sloan Kettering Cancer Center (MSKCC) and University of Pittsburgh, USA. He is now the Deputy Chief of Thoracic Surgery at the MSKCC and Member in Center for Cell Engineering at MSKCC. He has published more than 100 papers in reputed journals including JCO and JNCI. He is invited to be the Deputy Chief Editor for Molecular Therapy Oncolytics Journal (Nature Group Publication) serves as an editorial board member of PLOSOne.
Chemo immunotherapy for lung cancer/mesothelioma
Pathology and cell biology of pediatric tumors; anatomic pathology bone cancer(ewing sarcoma)
Amedeo Amedei is a researcher of Department of Experimental and Clinical Medicine (University of Florence - Italy) section of Internal Medicine from 2005. He has completed his B. A in Biological Science at Florence University, Italy, (1996) and has received a PhD in Experimental and Clinical Medicine from the Florence University, Italy in, 2003. Amedei is a teacher at the University of Florence in different courses: Immunology, General Pathology and Immunology, Immunology and Immunohematology, Immunology and Immunological Techniques, Biology and Infectious diseases. Component of the teaching Ph.D. in Clinical and Experimental Medicine, in the Federated School of Allergy and Clinical Immunology of the Florence Faculty of Medicine and in the international Erasmus course on "Oncology" (2006, 2007). The expertise areas of Dr. Amedeo Amedei are the immunology, infection diseases and oncology. He is serving as an editorial board member of 18 reputed journals and reviewer of 28 international journals.
Clinical immunology; signaling pathways; cancer therapy; tumor immunology immune t response in cancer; immune response human bacterium infection(gastric cancer, acute lymphocytic leukemia)
Dr. Aminisani is assistant professor of cancer epidemiology in the department of statistics and epidemiology at Tabriz University of Medical Sciences, She has earned her BSc in Nursing from Shahid Beheshti University; MSc in Epidemiology from Shiraz University, Iran and PhD degree in Medicine from University of Sydney. Her interest areas of research include cancer epidemiology, cohort studies, life style factors, quality of life and patterns of care in cancer patients.
Epidemiology; screening and diagnostic tests; breast cancer; colon cancer
Alexandre Arcaro is a group leader at Bern University Hospital. He graduated at the University of Lausanne and obtained a Ph.D. from the University of Fribourg. He was then a postdoc at the Ludwig Institute for Cancer Research, UCL and Lausanne Branch. He was then a lecturer at Imperial College London. Subsequently, he was a group leader at the University Children's Hospital Zurich.
Common tumors in children include leukemia; brain tumors and neuroblastoma
Dirk Arnold is Director of the Dept. Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany. Before taking this position, he was 2010 appointed as Director of the University Cancer Centre in Hamburg (UCCH) and held positions at the University Departments for Oncology and Haematology in Halle-Wittenberg and Berlin. His major field of scientific interest are gastrointestinal cancers, and here specifically modern therapeutic approaches in biomarker-driven decision processes, and multimodal treatment strategies, also including other specialities. Here, he serves as chairman of Colorectal Cancer Study Group of the German AIO, a major collaborative group in clinical oncology. Within the AIO framework, he served as founding member of the Central Clinical Trials Office, underlining his expertise also in methodology of clinical research. Furthermore, his interest is the organisation of larger collaborative research structures and of integrated cancer centre networks. Prof. Arnold is also member of the American Society of Clinical Oncology and Task Force Member of the National Cancer Institute, as well as Board member of the EORTC GI study group.Furthermore, he is board member of the German Society of Haematology and Medical Oncology (DGHO), and member of the German Cancer Society.Within ESMO, since 2012 he is section editor for GI cancers in the Guidelines Committee and Associate Editor with .
Oncology and hematology; gastrointestinal cancers: chemotherapy; monoclonal antibodies; interventional treatment; radiotherapy; chemotherapy in colon metastatic cancer
Dr. Rossana Berardi is Assistant Professor of Medicine & Surgery at the Clinic of Medical Oncology, University of Marche , AOU United Hospitals of Ancona , Italy. She achieved her degree in Medicine Surgery at the University of Ancona in July 1997. Dr. Rossana Berardi received Diploma in Ultrasound, released by the Italian Society for Ultrasound in Medicine and Biology (SIUMB) in 1998. She completed her postgraduate Diploma in Oncology at the Postgraduate School of Oncology, University of Ancona by 2001. Dr. Rossana Berardi has served on many review panels, has reviewed for many journals. Dr. Rossana Berardi has over 168 peer reviewed publications. Dr. Rossana Berardi research interests include Oncology, Immunology, Cancer Research, DnA damage & Repair.
Clinical and translational research on treatment of solid tumors and on prognostic factors; research on SIADH; prostate cancer; breast cancer; colon cancer; renal cancer; glioblastoma; liver cancer
Head and Neck tumors; skull base tumors; skin cancers
Currently, effective disease management in the United States does not exist for colon cancer peritoneal carcinomatosis PC with dismal prognosis and overall median survival of 6 months. Clearly, there is a need to develop novel targeted strategies to treat PC. The Prof's research focuses on developing novel anti-cancer targeted therapies which began in 2005 with Matthew R. Pincus, MD, PhD from the Department of Pathology and Laboratory Medicine from the Brooklyn Veteran’s Administration Hospital and Downstate Medical Center. The Prof Bowne employed a computer-based molecular modeling approach to design peptides from p53 proteins that induce tumor cell necrosis without affecting normal cells. PNC-27 containing HDM-2-binding domain of p53 residues 12-26 attached to a cell membrane penetrating sequence called penetratin or membrane residency peptide (MRP) on its carboxyl terminal end induces tumor cell necrosis by pore formation in cancer cell membranes by PNC-27 binding to membrane bound HDM-2. This selective anti-cancer activity is likely due to overexpression of HDM-2 in cancer cell membranes that does not appear to occur in normal untransformed cells. PNC-27 has been shown to effectively block MIA-PaCa-2, TUC-3, and A-2058 cells while having no effect on untransformed cells including AG13145 primary human fibroblasts and BMRPA1 cells. Importantly, its closely related truncated peptide PNC-28 (p53 residues 17-26) was shown to eradicate highly malignant peritoneal TUC-3 tumors in nude mice with no apparent side effects. Thus, our preliminary data demonstrates that PNC-peptides derived from the HDM-2 binding domain may have promise as a targeted intra-peritoneal anti-cancer approach for lethal colon cancer PC as well as other peritoneal surface malignancies. Our current research design will extend our preliminary results with these peptides to a translational murine model for colon cancer PC and ovarian cancer. This translational research is directly applicable to our developing and clinically productive peritoneal surface malignancy program at the DUCOM. The opportunity to submit an application to ACS to develop novel treatment strategies for colon cancer peritoneal carcinomatosis is timely and exciting; worthy of translational experimental validation.
Surgical oncology; pancreatic cancer; leukemia
Dr. Camphausen received his M.D. from Georgetown University in 1996. He completed his internship at Georgetown in 1997 and a residency in radiation oncology at the Joint Center for Radiation Therapy at Harvard Medical School in 2001. Dr. Camphausen spent two years working in the laboratory of Dr. Judah Folkman studying the interaction of angiogenesis inhibitors and radiotherapy. He joined the National Cancer Institute in July 2001 as a tenure-track investigator. He served as the deputy branch chief beginning in April 2004 and was appointed to branch chief of the Radiation Oncology Branch in 2008. Dr. Camphausen is board certified by the American Board of Radiology.
Radiotherapy; glioblastoma multiforme; HDAC; radiation sensitizers; biomarkers; prostate cancer; brain metastasis and treatment
Amancio Carnero was awarded with his Ph.D. in Molecular Biology at the Univesidad Autónoma de Madrid, Spain, in 1994, for work on ras signal transduction pathway at the Instituto de Investigaciones Biomédicas (CSIC). He moved to the Cold Spring Harbor Laboratory, USA, where he worked on strategies of gene isolation based on function in mammalian cells. Armed with a long term Postdoctoral Fellowship granted by the European Molecular Biology Organization (EMBO), the period 1997-2000 was also spent as Senior Research Fellow at the Institute of Child Health, London, UK. His research interests focused on the cell cycle, replicative senescense and cellular immortalisation. Dr. Carnero was to spend one further year in London based at the Wolfson Institute for Biomedical Research, as Senior Lecturer, before returning to Spain in 2001 to assume his position as Head of the Assay Development Group at the Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid. At the end of 2009, Amancio moved from Madrid to the Biomedical Institute of Seville (IBIS/CSIC) to lead the Molecular Biology of Cancer Lab. Current research focuses on the identification of new genes involved in cancer, its characterization and traslation to clinic, and the identification and validation of new targets for anticancer drug discovery. The work involved Molecular and cellular biology, genetically ingeeniered mouse models, molecular pathology and traslational studies.
Identification and characterization of genes with diagnostic or theraputic relevante in cancer; establishing causality in the tumoral process; cellular senescence and immortalisation;validation of new therapeutic targets; thyroid cancer; colon cancer; lung cancer; breast cancer; melanoma
Roberto Castelli MD, is an assistant professor of Internal Medicine at the University of Milan. He graduated “cum laude” from the University of Milan in 1991. He completed his post-graduated speciality in Hematology and Internal Medicine at the University of Milan. He is involved in research on prognostic, therapeutic and biological aspects of hematological disorders. The scientific work was conducted mainly in the field of autoimmune haematological diseases such as autoimmune cytopenias, effects of immunomodulatory drugs in Multiple Myeloma and lymphoprolipherative diseases, autoimmune manifestation in the setting of B cell chronic lymphocytic leukemia, and B or T cell Lymphomas Roberto Castelli researchs are also involved in the link between autoimmunity and lymphoprolipheration, particularly on C1 inhibitor deficiencies and lymphoprolipherative disorders. He has published around 50 original papers all included in PubMed, some of excellence as Autoimmunity review, Journal of Allergy and Clinical Immunology, Haematologica, Blood, American journal of Hematology). Teaching in Haematology and Internal Medicine in various degree courses and speciality of the faculty of Medicine University of Milan. Clinical activity in Haematology and Coagulopathies division University Hospital of Milan.
Lymphoprolipherative disease; multiple myeloma; immunomudolatory drugs; complement; C1-Inhibitor deficiency; B cell lymphocytic leukemia
Dr. David W. Chan is currently an Assistant Professor in the Department of Obstetrics & Gynaecology, The University of Hong Kong. He received his PhD from Monash University, Australia in 2002. He completed postgraduate training in molecular oncology at Peter MacCallum Cancer Institute in Melbourne and in Department of Pathology, the University of Hong Kong from 2002 to 2005. He had been a Research Assistant Professor from 2006 to 2013 and was promoted to Assistant Professor in 2014 in Department of Obstetrics & Gynaecology, the University of Hong Kong. His main research interests include functional characterization of tumor suppressors and oncogenes and delineation of the related cellular signaling pathways which contribute to the tumorigenesis of gynaecological malignancies. He is particularly interested in the impacts of cancer cell metabolism and tumor microenvironment on ovarian cancer metastasis, development and chemoresistance.
gynaecological malignancies, chemoresistance, metastasis, cancer cell metabolism, tumor microenvironment, AMPK, FOXM1
Dr. Chun Hei Antonio Cheung is an Assistant Professor of Pharmacology in the National Cheng Kung University College of Medicine in Taiwan. He graduated with a PhD degree from the University of Auckland in New Zealand, and subsequently undertook his post-doctoral studies in the National Health Research Institutes in Taiwan. He is member of various scientific societies including The Royal Society of New Zealand, American Association for Cancer Research, European Association for Cancer Research and Hong Kong Institution of Science. Dr. Cheung has published both research and review articles in international journals such as PLoS ONE, Molecular Cancer, Cancer Letters, Current Medicinal Chemistry, Investigational New Drugs, and Expert Opinion on Investigational Drugs. He is the guest/managing editor of the journal Frontiers in Bioscience.
Colon cancer; breast cancer; hepatic metastasis of colon cancer; prostate cancer; chemotherapy in breast and colon cancer
Prof James Chim is a clinician scientist interested in clinical and translational studies in myeloma, leukemia and lymphoma. Currently, he has published >200 papers in pee-reviewed journals including Blood, Journal of Clinical Oncology, Leukemia, etc. Prof Chim is interested in the scientific studies of DNA methylation in haematological cancers, on which he has published >45 papers including seven reviews. Moreover, he is interested in clinical studies of multiple myeloma, lymphoma and leukemia. He is Clinical Professor in the Department of Medicine, Queen Mary Hospital, University of Hong Kong. He is also a Board Member of the International Myeloma Working Group (IMWG) and Chairman of Education Program, Asia Pacific Hematology Consortium (APHCON). He is the Founding Chairman of the Hong Kong Society of Myeloma. He is the Editor-in-Chief of Journal of Genetics Study, Associate Editor of Hematology, and is/has been on the editorial board of multiple journals including Carcinogenesis, Journal of Hematology & Oncology, Bone Marrow Transplantation, Journal of Translational Medicine, Translational Oncology, Epigenomics, PLoS ONE, Current Oncology Reports, etc. Prof Chim was awarded the State Scientific and Technological Progress Award in 2009, and is Visiting Professor to Peking University People’s Hospital, Beijing People’s Liberation Army 301 Hospital, Suzhou University, Shandong University, Tongji Medical College and Sun Yat-Sun Institute of Hematology. Finally, he was an invited reviewer for ASH meeting in Orlando, 2011, and has been the external reviewer for grant applications from funding agencies including Leukaemia & Lymphoma Research, Leukemia Research (United Kingdom), Cancer Research United Kingdom, The Agency for Science, Technology and Research (A*Star) of Singapore, and Association for International Cancer Research (AICR) and Czech Science Foundation.
Myeloma; haematological cancers
Dr. Ezharul H. Chowdhury is currently holding an Associate Professor position and a cluster leader of 'Biomedical Engineering' under Advanced Engineering Platform (AEP) at MONASH University (Sunway Campus). Prior to this appointment, he was a Senior Lecturer at International Medical University (IMU) since September 2008 and an independent Assistant Professor of Tokyo Institute of Technology (Tokyo Tech) as well as a Visiting Professor at Shizuoka Cancer Center Institute since 2006. He was awarded with 'Doctor of Engineering' in 2003 by Tokyo Tech where he also carried out a post-doctoral study and subsequently, served as a team leader. He has pioneered the development of a range of pH-sensitive inorganic nanoparticles as smart tools for efficient and targeted intracellular delivery of genetic materials, gene-silencing elements, proteins and classical anti-cancer drugs. He is currently applying this smart nanotechnology for the treatment of cancer, particularly breast carcinoma, and diabetes. His team is now conducting pre-clinical trials with some interesting nano-formulations of classical anti-cancer drugs, therapeutic gene(s) and anti-sense RNAs (siRNAs). His research team is thus one of the leading groups in the world, having original and unique contributions in this multidisciplinary field. Currently he is supervising 8 PhD students and 1 Master student. His research projects have so far been funded internally through institutional grants as well as externally by the Japanese Government's Ministry of Education, Culture, Sports, Science & Technology (MEXT), Japan Society for the Promotion of Science (JSPS), the Malaysian Ministry of Science, Technology and Innovation (MOSTI) and Ministry of Higher Education (MOHE). He works as editorial board members for 5 international journals. His outstanding contributions have so far produced over 65 publications in the international journals of high repute.
Biodegradable inorganic nanosized particles and utilizing them in the delivery of multiple therapeutics, such as gene, protein, antisense oligonucleotide or siRNA (Small interfering RNA) and conventional drugs; cervical cancer;lung cancer; breast cancer
Dr. Maria R. Ciriolo is currently holding a Full Professor position at the University of Rome “Tor Vergata” Rome, Italy. Prior to this appointment, she was Full Professor, University of Chieti “G. D’Annunzio”, Chieti, Italy since 1994 and Research associate, Yeshiva University, New York, NY (USA) since 1986. She was awarded in 1988 for her performance of duties as Research Associate in Molecular Pharmacology from Albert Einstein College of Medicine, New York, USA. She has qualified expertise in several issues related to cellular and molecular redox-mediated processes involved in apoptosis, cell cycle regulation and signal transduction, as validated by several publications in high-ranking journals. Moreover, she contributed to the discovery of the cytotoxic action of bleomycin as ROS producer and catalyst of DNA damage. Her past experience deals with the role of: a) antioxidant enzymes in various physiological and pathological conditions such as ageing and cancer; b) glutathione in intracellular copper delivery c) Cu,Zn superoxide dismutase as copper-buffer system; d) redox state on different viruses replication, as confirmed by the discovery of antiviral effect of exogenous glutathione; e) glutathione and nitric oxide in the molecular mechanisms of apoptosis in neurodegeneration and cancer; f) oxidative and nitrosative stress in the regulation of signal trasduction pathways involved in cell cycle regulation, autophagy and apoptosis. Her research projects have so far been funded nationally and internationally. She works as editorial board members for 6 international journals. Her outstanding contributions have so far produced over 170 papers on high-ranking journals; 20 book chapters and 120 abstracts of International and National Congresses. (H-index 43, Total citations > 7500 from ISI Web of Knowledge).
Nitric oxide metabolism and regulation of nitric oxide synthases;interplay between redox and phosphorylative signaling in tumor;neuronal cell death and viral infections; - De-regulated metabolism (lipid, amino acids, glucose) of cancerous cells; brain cancer; cancer therapy
Brain metastases imaging; early diagnosis and early bio-markers of brain metastases
Endocrine tumor disorders
Glioma; pancreatic caner therapy; mesenchymal stem cells in cancer therapy
Dr. Konstantin Dragnev is a medical oncologist in Lebanon, New Hampshire and is affiliated with Dartmouth-Hitchcock Medical Center. He received his medical degree from Medical University of Sofia FOM and has been in practice for more than 20 years.
Medical oncology/ hematology; aerodigestive tract cancer; lung cancer; brain metastases
Plasma cell dyscrasias multiple myeloma; immunotherapy myeloma; brain metastasis and treatment
Prof. Tomas Eckschlager, Deputy head for education, head of Laboratory of biology of solid tumors, works in Department of Pediatric Heamatology and Oncology, 2nd Medical Faculty, Charles University and University Hospital Motol. His main interests are: molecular biology and genetics of pediatric cancer; experimental therapy of cancer and research of cancer cell chemoresistance; clinical pediatric oncology and late effects of children cancer therapy.
molecular biology and genetics of pediatric cancer; clinical pediatric oncology
Leigh Ellis conducted my Ph.D. studies at the Peter MacCallum Cancer Centre in Melbourne Australia through the Australian National University with Dr Ricky Johnstone. The focus of his Ph.D. work was investigating the apoptotic mechanisms and clinical efficacy of histone deacetylase (HDAC) inhibitors. He joined the lab of Dr. Roberto Pili to carry out my postdoctoral studies in 2008 at Johns Hopkins before moving to Roswell Park Cancer Institute in 2009, where he was the recipient of a Department of Defense postdoctoral fellowship. His primary studies with Dr Pili involved the investigation of novel targeted therapy combinations for the treatment of advanced genitourinary malignancies. He is a current Prostate Cancer Foundation Young Investigator. Using mouse model and genomic approaches his independent research focuses on 3 major themes involving cancer. 1) Epigenetic mediated dedifferentiation in prostate cancer initiation; 2) Insertional mutagenesis mouse models to discover genes underlying drivers of aggressive prostate cancer and 3) Preclinical testing of targeted and gene therapy approaches to treat aggressive prostate cancer and lymphoma.
Genetic/epigenetic mechanisms of aggressive cancer; b-cell lymphoma and prostate cancer
Mirco Fanelli is Associate Professor of Technical Sciences of Laboratory Medicine at the University of Urbino, He graduated in Biological Sciences at the University of Camerino in 1994. He obtained in 1996 a PhD position at the European Institute of Oncology (Milan, Italy) and contributed to the understanding of molecular basis of the leukemogenesis (APL model). In the last years his research activity was focused in two important fields: 1) the development of new experimental strategies (PAT-ChIP) that can allow the identification of epigenetic profile of cancer in complex biological models (e.g. FFPE-tissues, microdissected samples, etc.); 2) the identification and characterization of new synthetic compounds able to interfere with the chromatin structure with the aim to develop novel therapeutic strategies against cancer.
Glioblastoma; liver cancer; breast cancer; cancer epigenetics, PAT-ChIP, cancer treatment
Yujiang Fang joined the DMU department of microbiology and immunology in December 2013. He received his M.D. and Ph.D. in China and has worked as an attending urologist for years. Following postdoctoral training in pathology in Paris and postdoctoral training in immunology in Columbia, Missouri, he was a research assistant professor at the University of Missouri and adjunct assistant professor at several other universities. A member of the editorial boards of several established journals, Dr. Fang has extensive involvement in clinical, teaching and research experiences. He is interested in cancer immunotherapy, the effect of radiosensitizers on cancer and the mechanisms of resolution and fibrosis of inflammation.
Molecular biology; cell biology; immunology; melanoma; prostate cancer
Nuclear medicine; cholangiocarcinoma; neuroendocrine tumors; ileal adenocarcinoma; brain tumors; colon cancer; liver metastasis; lung cancer; lung metastasis treatment
Minoru Fukuda is Department Head of Chemotherapy at Nagasaki University Hospital, and Vice General Manager and Associate Professor of Nagasaki University Clinical Oncology Center. He is councilor and publicity member of Japanese Society of Clinical Oncology, and councilor and guideline member of Japan Lung Cancer Society.
Lung cancer; lung adenocarcinoma
Ourania Nicolatou-Galitis is Professor and Chair of the Dental Oncology, at the National and Kapodistrian University of Athens, Greece. She is President of the International Society of Oral Oncology and serves as Chair of the Bone Study Group, MASCC.org. Osteonecrosis of the jaw in medication is her major research interest.
Field of oral oncology; burden of oraloucositis; osteonecrosis of the jaws in oncology patients; oral complications in cancer therapies;oral care in cancer;oral care in HSCT recipient;quality of life in cancer; oral lesions in special care patients; leukemia; brain cancer
Renal cell carcinoma; bladder cancer; kidney cancer
Brain metastases from breast cancer; non-small cell lung cancer; melanoma and renal cell carcinoma
Immunotherapy for prostate cancer and colon cancer; cancer biomarker discovery and validation
Dr. Brunilde Gril is a staff scientist in the Women’s Malignancies Branch, Center for Cancer Research, NCI, USA. Prior to joining NCI, Dr. Gril received her PhD in Molecular Pharmacology in 2006, from the University of Paris René Descartes, France. Dr. Gril has worked for more than ten years on translational research investigating brain metastases of breast cancer with a multifocal approach. The overarching theme of her research involves identifying molecular targets, determining mechanism of action, deciphering signaling pathways, and preclinical testing of developmental therapeutics in mouse models of brain metastases of breast cancer. Since four years, Dr. Gril focused her research on the investigation of the molecular underpinnings of altered blood-brain barrier permeability, in order to eventually develop strategies to improve drug uptake. She received several awards from different organizations such as AACR and ASCO, and received the NCI Director’s Intramural Innovation Award in 2012.
Tumor cell signaling pathways to identify oncology targets and biomarkers; tumor microenvironment; molecular basis for experimental therapeutics and translational study; brain metastatic breast cancer; Her-2; VEGFR and EGFR signal pathway; blood-tumor barrier and blood-brain barrier
Head oncology; immunology; hematology; leukemia; brain tumors
Cancer research; viral oncology; molecular medicine; melanoma; melanoma metastases; renal cancer
Dr. Osamu Hiraike belongs to the Department of Obstetrics and Gynecology Graduate School of Medicine The University of Tokyo.He is an Associate Professor of Graduate School of Medicine The University of Tokyo. He has received a PhD in Medicine from the University of Tokyo Tokyo Japan in 2001-2002. He is serving as an editorial board member of reputed journals and reviewer of journals organs Fertility and treatment.
Obstetrics and gynecology; ovarian cancer; cervical cancer; breast cancer
Radiopharmaceuticals; radiation biology; instrumental methods of analysis; radioprotective study in animal; cell culture and human lymphocytes; tumor bearing mice; cytogenetic methods (micronuclei in mice bone marrow and binulcated lymphocytes); glioblastoma; ovarian cancer; bladder cancer
Lung metastases; chemotherapy and scar irradiation in breast cancer lymphoma; gastric cancer; metastatic colon cancer; bone metastases; soft tissue sarcomas; renal cancer; pancreatic cancer; radiotherapy with bone metastasis
Dr Egidio Iorio is a Researcher of Department of Cell Biology and Neurosciences at the Istituto Superiore di Sanità (Rome- Italy). Master Degree in Biological Sciences and Specialization in Clinical Pathology at University of Rome "La Sapienza". PhD in Biochemistry and Molecular Biology at University of Rome "Tor Vergata". The main research interests of Dr Iorio were focused on alterations in metabolism in relation to cell differentiation, tumor growth and cell death. He is actively involved in projects to develop original molecular imaging methods for the identifications of magnetic resonance spectroscopy biomarkers of tumour cell proliferation and response to therapy.
Biochemistry; magnetic resonance spectroscopy; metabolomic; lipid and glucose metabolism; cell signaling.
Hepatocelullra carcinoma; portal hypertension; IVR
Small molecule inhibitors; target therapy; tumor suppressors; tumor animal models; hypoxia; oncoproteins; serpins; membrane transport; lipid metabolism; recombinant protein expression; cell signaling pathways; deubiquinases, ubiquitination and protein degradation; proteomics therapy for pancreatic and oral cancer
Oh Jeong is an associate professor of Department of Surgery, Chonnam National University, South Korea. He earned a MD and PhD in Medicine at Chonnam National University, Korea in 2008. His specialty is surgical oncology especially regarding the gastric cancer. He has published numerous papers regarding surgical treatment and pathophysiology of gastric cancer. He also do a lot of clinical research in diverse upper gastrointestinal disease. Oh Jeong has served as a boarding member of many national and international surgical society.
Gastric cancer; upper gastrointestinal malignancy; minimal invasive surgery; robotic surgery; cancer pathogenesis; molecular carcinogenesis
Dr. Kanwar earned his PhD from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. In 1997 he joined as Research Fellow in The University of Auckland, Newzealand. In 2002 he joined as Senior Scientist/Senior Research Fellow in The University of Auckland. Currently he is Associate Professor of Immunology & Cell Biology in Institute of Technology Research and Innovation, Deakin University, Australia. Kanwar's research work generated in total of 8 patent/PCTs with two provisionals in preparation. Five of these patents have been licensed for commercialization to biotech companies Antisoma, NeuronZ, Neuren Pharmaceuticals and Fonterra.Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 110 publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books. Prof Kanwar’s research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1α and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; autoimmune diseases; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed by his group. Kanwar’s main research objective is to understand and target the mechanisms involved at the molecular and sub cellular level which gives us an edge over the prevalent targeting techniques. He carries out both academic and commercial research projects and develops new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems. His recent research focus on locked nucleic acid (LNA) LNA-modified aptamers conjugated "double targeted nano-bullet nanocapsules" with natural anti-tumour proteins which specifically target cancer cells.
Nanomedicine; locked nucleic acid (LNA)-aptamers; nano-nutraceuticals; cancer stem cells; biomarkers; nanocapsules; siRNA; miRNA; micro-fluidics and lab-on-a-chip devices
Christiana Kartsonaki is a Senior Statistician at the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) in the Nuffield Department of Population Health, University of Oxford, working on the China Kadoorie Biobank.
She has a degree in Mathematics, an MSc in Applied Statistics and a DPhil in Statistics. She has previously worked in the Department of Oncology of the University of Oxford and at the Centre for Cancer Genetic Epidemiology in the Department of Public Health and Primary Care of the University of Cambridge.
Statistical analysis for various types of studies on cancer; oesophageal cancer
Lung cancer; pancreatic cancer; colorectal cancer; cancer chemotherapy
Prostate cancer; breast cancer
Rajeev Kumar was graduated from Jawaharlal Nehru University (JNU), New Delhi, India in 2011. Currently, working as Associate Professor (PI) at The Affiliated Hospital of Guizhou Medical University, Guizhou, China. His research interest is translational immunotherapy and drug molecule signalling mechanism in oncology area;
• T cell receptor (TCR) costimulatory inhibitors such as PD-1/CTLA4/ICOS/LAIR-1,
• Improve impaired functions of engineered T cells and CTLs for cancer immunotherapy,
• Role of miRNA in cancer proliferation and metastasis as therapy response biomarker,
• Chemopreventive role of selective estrogen receptor modulators (SERMs) and phytoagents in BPH/prostate cancer; brain metastasis and treatment
Gynaecological oncology; human papilloma virus and diseases of the genital tract; Impact of novel surgical techniques (e.g. laparoscopy or fertility sparing) in the treatment of women’s cancers; breast cancer; ovarian cancer
Dr. Yasuhiro Kuramitsu is the associate professor in Department of Biochemistry and Functional Proteomics, Graduate School of Medicine, Yamaguchi University, Japan. He earned his Ph.D. at Hokkaido University, Sapporo, Japan. He has published more than 80 reviewed papers. He served as a reviewer and an editor of peer-reviewed journals in the area of proteomics, gastroenterology and oncology.
1. Proteomic profiling of pancreatic cancer for biomarker discovery in therapy; 2. Proteomic profiling of scirrhous type gastric cancer for biomarker discovery in therapy; 3. Proteomic profiling of malignant pleuralmesothelioma for biomarker discovery in therapy; 4. Method development for protein chip; gastric cancer; pancreatic cancer; renal cancer; liver cancer
Athanassios P. Kyritsis, MD, DSci, is currently Professor and Chairman at the Dept. of Neurology of the University of Ioannina, School of Medicine, Greece. Dr. Kyritsis received his MD from the University of Athens Medical School, Athens, Greece, in 1978 and his DSci degree from the same University in 1988. From 1981 to 1986 he was a post-doctoral fellow at the National Eye Institute, Bethesda, Maryland, and from 1986 to 1990 he did his residency in Neurology at the University of Wisconsin Medical School, Madison, Wisconsin, USA. Subsequently he did a clinical fellowship at the Department of Neuro-Oncology at the University of Texas M. D. Anderson Cancer Center in Houston, Texas, and then he served as Assistant and Associate Professor at the same department from 1992 to 1999. In 1999 he moved to the Department of Neurology at the University of Ioannina as Professor and Chairman of Neurology
brain metastasis and treatment
Melanoma, sarcoma and therapy in gastric cancer
Gregory Lee was professor at University of British Columbia in Vancouver, Canada until 2012. He received his PhD in physical biochemistry from California Institute of Technology Pasadena, CA in 1972. His major research interest is in the field of biotechnology. He has generated numerous monoclonal antibodies for immunodiagnostic and therapeutic applications, including the early pregnancy detection, ovulation, myocardial infarction and cancer. During the last decade, he has been focused on research and development of the monoclonal antibody-based anti-cancer drugs (noticeably RP215 and GHR106) for immunotherapy of human cancer. He has been serving as editors of several international journals related to cancer research since 2012.
Cancer immunology antibody-based anti-cancer drugs immunotherapy of ovarian cancer; lung metastasis treatment
Gary Li has nearly 20 years’ experience in biomedical research and pharmaceutical research and development. He is currently Executive Director, overseeing all discovery and translational research efforts at Ignyta, Inc., a clinical-stage, precision oncology company located in San Diego, California. Before joining Ignyta, Gary spent 10 years at Pfizer and 1 year at Johnson & Johnson, playing multiple key roles in cancer research and drug discovery with increasing responsibilities. Gary obtained his Ph.D. from the University of Pennsylvania, School of Medicine in 2003. He holds multiple patents and has published over 40 peer-reviewed articles in top science and medical journals and delivered over 60 invited talks and meeting presentations.
Cancer biology and therapeutics
cancer genomics; pharmacology; biomarkers; resistance; drug discovery; translational research; melanoma; translational oncology
Notch signalling in cancer biology; hypoxia pathways; tumour angiogenesis and metastasis; tumour multidrug resistance; microRNAs in cancer biology; ringI-finger E3 ubiquitin ligases in tumourigenesis and metastasis; experimental mouse tumour models; gastric cancer; breast cancer
Ascites carcinomas; tumor hypoxia; thyroid cancer therapy; lung cancer; colon cancer; breast cancer
Dr. Shuen-Kuei Liao earned his PhD degree from McMaster University, Canada, and subsequently received his postdoctoral training at University of Toronto. He has been working in the areas of cancer biology and immunotherapy in Canada, USA and Taiwan over the past three decades. Currently he is Professor at Taipei Medical University with his interests in cancer stem cells and immunotherapy, and the roles of mesenchymal stem cells in transplantation.
Cancer biology and immunology; immunotherapy for cancer; melanoma; retinoblastoma, glioblastoma; germ cell tumor metastatasis and treatment
Dr. Lim is currently full Professor (1996- ), Department of Biochemistry, Chungnam National University School of Medicine, Korea. He is one of the leading scientists in the field of a research on the Omega-3 fatty acids and Cancer. He had researched on regulation of metastasis- and angiogenesis-related genes in several cancers. Since 2015, he has worked to identify novel molecular mechanisms of anticancer action of omega-3 fatty acids in several cancers. He published many peer review papers and several books’ chapters on Omega-3 Fatty acids and Cancer. In 2010, he organized Korea-EU International Forum on Omega-3 fatty acids and Cancer.
Anticancer and antimetastatic effects of 3-polyunsaturated fatty acid Inflamation and cancer (PGE2 and Wnt signaling); Regulation of metastasis-specific gene; Development of antimetastatic and antiangiogenic proteins ; prostate cancer; oral cancer ; liver cancer; colon cancer; cervical cancer
Myong Cheol Lim, M.D., Ph.D. is the gynecologic oncologist and staff surgeon at the National Cancer Center, Korea. Dr. Lim’s clinical expertise includes the surgical management of gynecologic cancers, including ovarian, fallopian, primary peritoneal, cervical and endometrial cancer. He is one of the pioneers of cytoreductive surgery for peritoneal cancer such asovarian cancer, pseudomyxomaperitoneii, and mesothelioma. Dr. Lim’s main research interests are 1) Surgery and targeted therapyfor gynecologic cancers, 2) Minimal invasive surgery, laparoscopic and robotic surgery, and natural orifice trans-luminal surgery (NOTES), anddevelopment of surgical instrument, 3) Hereditary/familial (gynecologic) cancers 4)Cancer statistics,patterns of health care delivery, and clinical guideline,5) Cancer survivorship: sexuality, lymphedema, exercise, sarcopenia, and secondary cancer.
1. Cytoreductive surgery for gynecologic cancer, mesothelioma, and pseudomyxoma peritonei
2. Minimal invasive surgery, laparoscopic / robotic surgery, and natural orifice trans-luminal surgery (NOTES)
3. Hereditary/familial (gynecologic) cancers
4. Cancer survivorship: sexuality, lymphedema, exercise, sarcopenia, and secondary cancer5. Hyperthermia6. Development of surgical instrument;colon cancer
Prostate cancer and other genitourinary cancers;
early phase clinical trials and drug development;
cancer immunotherapy; epigenetics and angiogenesis targeted therapy;
chemotherapy with prostate metastasis
Yiyao Liu is a professor of Biophysics and the vice dean in the School of Life Science and Technology, University of Electronic Science and Technology of China (UESTC). He received his Ph.D degree from Gunma University of Japan and finished his postdoctoral training from the Institute of Health Biosciences, School of Medicine, Tokushima University of Japan, in 2004 and 2007, respectively. He joined the UESTC in 2004 as an associated professor, and promoted to full professor in 2008. His research interests include nanomedicine for cancer diagnosis and therapy, smart nano-biomaterial design, and cancer cell-tumor microenvironment interactions and its signal transduction
Nanomedicine for cancer molecular; diagnosis and therapy; cancer cell signal transduction in hematogenous metastasis; tumor cell; microenvironments
cancer nanomedicine for therapy and diagnosis nano-probes and molecular imaging for cancer;ovarian cancer; breast cancer; micro-fluid chip in detecting micrometastasis of non-small-cell lung cancer
Dr. Lococo is a thoracic surgeon with a wide experience in lung cancer research. He carries out his clinical and surgical activity in the Comprehensive Oncological Cancer Center of Reggio Emilia (Italy). He has proven remarkable leadership skills in thoracic tumors; in his Centre, he is a group leader of 3 Multidisciplinary Oncologic Teams of Research (Lung Tumors, Neuroendocrine Thoracic Neoplasms and Malignant Pleural Mesothelioma); he is winner of the following competitions:
1. “Young Investigator Travel Grant” at “112th JSS-Annual Congress (2012) and at “3° ITMIG World Congress”in Japan (2012).
2. “Mario Selli” Award as best Italian young (under 35) researcher in 2012
3. “Masaoka Award”: best oral presentation at “3° ITMIG World Congress”in Japan (2012).
4. Post-doctorial Fellowship of the "Fondazione Veronesi".
5. Selection for the “Young Investigator Award” at “21th-22th-23th-24th ESTS Conferences (2012-2013-2014-2015-2016).
Oncologic thoracic surgery; epithelial tumors; thymoma; fibrous tumor of the esophagus; liposarcoma
Cancer biology; colorectal cancer; cancer biomarkers; cancer diagnostics; cell signaling; molecular and cell biology that underlies tumor growth; tumor progression and response to cancer therapy; breast cancer and glioblastoma; the most common and deadliest brain malignancy in adults; prostate cancer biology and experimental therapeutics
Dr. Macha did his Masters in Biochemistry from Jamia Hamdard, New Delhi, India. He qualified several National level competition exams and was awarded the Junior Research Fellowship (NET-JRF). In year 2005, he joined his doctoral program on Head and Neck Cancers (HNCs) in the Department of Biochemistry at All India Institute of Medical Sciences (AIIMS), New Delhi, India, which is a premier institute of biomedical research in India. During his five years of doctoral training, he worked on the (a) identification of early diagnostic/ prognostic markers (b) anti-cancer activities of natural products on smokeless Tobacco (ST)/nicotine induced oral cancer models (c) identification and characterization of biomarkers as surrogate end points in clinical trials using natural products for advanced HNCs. His doctoral work besides identifying early diagnostic/prognostic markers, facilitated the identification of several molecular targets of ST and nicotine using the in vitro models and provided the molecular basis for the use of GS for chemoprevention of oral carcinogenesis. After joining Dr. Batra’s lab as a post-doctoral fellow in 2011 at University of Nebraska Medical Center, USA, he is extensively involved in identifying the novel mechanisms and signaling alterations associated with mucins in HNC pathogenesis using in vitro and in vivo models. His studies have revealed that mucin MUC4 is differentially upregulated in HNCs and prevents cells from undergoing cell Senescence (cell cycle arrest) thereby increases cell proliferation and survival of HNC cells. Over all, with 10 years of research experience in HNCs, he is sure that his studies will help to unravel novel insights into the involvement of mucins in HNC pathogenesis, identify novel diagnostic/ prognosticators and therapeutic targets to combat this deadly disease.
Head and neck cancer; squamous cell carcinoma; pancreatic cancer; oral carcinogenesis; brain cancer
Dario Marchetti is Professor in the Department of Pathology & Immunology and Director of the CTC Core at Baylor College of Medicine. Dr. Marchetti’s bibliography includes 145 publications, numerous awards, and uninterrupted funding since 1991. He acts as Reviewer of the most relevant journals in cancer research, and on Editorial Boards of “Cancer Microenvironment, “Tumor Viruses”, “Vascular Cell”, “Cancer Letters”, and “Journal of Cellular Biochemistry”, among others. He serves on grant reviewing panels of the National Institutes of Health of USA and Italy, the U.S. Department of Defense, and is a grant Reviewer for other national and international Agencies.
Circulating tumor cells (CTCs); molecular determinants of brain invasion; angiogenesis; metastasis; melanoma metastasis; melanoma; brain metastasis
Professor Kefah Mokbel MS, FRCS specialises in the diagnosis and management of diseases of the breast, including breast cancer and cosmetic breast surgery. He is currently the Lead Breast Surgeon at The London Breast Institute of The Princess Grace Hospital and Consultant Breast Surgeon at St. George’s Hospital in London. He is also Professor of Breast Cancer Surgery (Honorary) at The Brunel Institute of Cancer Genetics and Pharmacogenomics. He was named one of Tatler magazines "Top Breast Surgeons" in their 2006 and 2007 Best Doctors Guide. He graduated from the University of London in 1990. After four years of basic surgical training at London teaching hospitals (the Royal Marsden, Charing Cross, and the Chelsea and Westminster Hospitals), he qualified as a Fellow of the Royal College of Surgeons (FRCS, England) in 1994. His higher surgical training in breast surgery was carried out in London (St. Mary’s and Barts, and The Royal London Hospitals). In 2000 he completed his accreditation and gained the certificate of completion of specialist training in general surgery with a special interest in breast and endocrine surgery. In 2000, he was also granted the Master of Surgery (MS) degree by The Imperial College of Science, Technology and Medicine for his research in the field of molecular biology of breast cancer. Following this specialist accreditation, he was appointed as a Consultant Breast and Endocrine Surgeon to St. George’s Hospital, and an Honorary Senior Lecturer in Surgery. In 2002, he was appointed a Professor at The Brunel Institute of Cancer Genetics and Pharmacogenomics (Brunel University, London, UK) in recognition of his contribution to breast cancer research. In 2005, he was appointed as a Reader in Breast Surgery at St. George’s University of London in recognition of his outstanding research contribution in the field of breast cancer.
Dr. Silvana Morello is Research Scientist in Pharmacology at the Department of Pharmacy, University of Salerno, Italy. She obtained a PhD in Science of Drug at the University of Naples “Federico II”, Italy. She was an academic visitor at the Medical School of the University of Sherbrooke (Québec), Canada in 2000 and at the National Heart and Lung Institute of the Imperial College of London, UK in 2003-2004 She is currently Professor of Immunopharmacology and Clinic Pharmacology at the Department of Pharmacy, University of Salerno, Italy.
Cancer biology and immunology; Cancer immunotherapy; melanoma.
Dr. Munker graduated from Medical School in Erlangen (Germany) in 1979. After research training in Munich, Los Angeles and Houston, he was appointed to the Faculty of Ludwig-Maximilian University in Munich. In 2002, he was appointed to the Faculty of Louisiana State University in Shreveport (LA). He has more than 135 peer-reviewed publications and wrote 19 books or chapters in books.
Hematology; oncology; leukemia; stem cell transplantation research
Soft tissue sarcoma; gastrointestinal stromal tumors; rare tumors; immunology; melanoma
Cancer genetics; renal cancer;
Cancer angiogenesis and metastasis; cancer stem cells and chemotherapy resistance; lung cancer; breasr cancer; liver cancer
Raditation oncology; radiotherapy for prostate cancer; renal cancer; radiotherapy for metastatic liver tumors
Dr. Mohamed I. Nounou serves the Appalachian College of Pharmacy (Oakwood, VA, USA) as an assistant professor of pharmaceutical sciences. His current research is focused on brain drug delivery, non-viral gene delivery, weight loss management, topical and transdermal drug delivery and quality of pharmaceuticals, nutraceuticals and cosmeceuticals.
Brain drug delivery; non-viral gene delivery; weight loss management; topical and transdermal drug delivery and quality of pharmaceuticals, nutraceuticals and cosmeceuticals
Colorectal cancer; colon cancer; cecal cancer; colorectal liver metastasis
Dr. Claudia Palena received her Ph.D. degree in Biochemistry from the National University of Rosario, Argentina, in 2000. She subsequently joined the NIH as a Postdoctoral Fellow in the Laboratory of Tumor Immunology and Biology of the National Cancer Institute, and was appointed as a Staff Scientist in 2008 and as a Tenure-Track Investigator in the same laboratory in August 2011. Dr. Palena's current research is focused on the development of novel immunotherapeutic approaches aimed at targeting critical events in tumor progression with the ultimate goal of designing vaccine platforms and combinatorial therapies for the prevention and/or treatment of metastases in human cancer.
Cancer immunotherapy; mechanisms of tumor progression; tumor resistance to therapies; prostate cancer; brain cancer; breast cancer; lung cancer
Molecular mechanisms underlying disease pathophysiology; molecular therapeutics & biomarker development; nutrition & disease prevention; leukemia; lung cancer; breast cancer
Dr. Carlo Patriarca served as a Staff Pathologist in Genova and Milan and now he serves as Director of the Division of Anatomic and Surgical Pathology of S. Anna Hospital, Como, Italy. He focused his past interests on the role of adhesion molecules in oncology and his present interests on uropathology.
GU pathology; mainly bladder and prostate carcinoma and role of adhesion molecules in invasion and metastatic processes
Dr. Pavlik is a graduate of the University of Denver, and received his PhD from the University of Tennessee, Knoxville. He received a NCI Public Health Service Fellowship at the University of Illinois, Champaign-Urbana, Illinois and was a Visiting Assistant Professor, Department of Physiology and Biophysics at the University of Illinois, Champaign-Urbana. He is an active lecturer in the College of Medicine and organizes and mentors summer intern research including students from Denison University, Penn State University, Transylvania University, Centre College, Vassar College, the University of North Carolina, Eastern Kentucky University and the University of Kentucky. He is a member of the Graduate College and serves on dissertation committees for the PhD degree. Dr. Pavlik is an author on over 100 peer reviewed publications, has presented at a number of prestigious international conferences, and has been funded by the NCI, the ACS and the VA. His research focus is on ovarian cancer screening and factors that affect screening accuracy and performance
Gynecologic oncology; ovarian cancer
Cancer drug discovery and cancer pharmacology; how the tumour microenvironment pose obstacles or offer opportunities for drug treatment; bladder cancer; colon cancer; chemotherapy in ovarian cancer
Glioma; nasopharyngeal cancer; nasopharyngeal carcinoma metastasis; liver cancer
Dr. Pravin D. Potdar's present interest is to study molecular profiling of Circulating Tumor Cells (CTC), Circulating Tumor DNA, Cancer Associated Fibroblasts and Cancer Stem Cells involved in metastatic process of cancers, and to see how this process can be reverted back to normal by using innovated technologies which include nanotechnology and nanomedicine.
Cancer stem cells & therapy; molecular diagnostics for cancer ; infectious diseases; neurological and genetic disorders; early detection markers for breast and lung cancer; molecular targeted therapies of cancer
Gastrointestinal cancers (gastric and colon cancers) and liver cancer; role of cancer stem cells and circulating cancer cells in liver and colorectal cancer Viral hepatitis; HBV and HCV infection and their relationship with hepatocellular carcinoma; chemoprevention of HCC stem cells; iPSCs; liver regeneration; fatty liver diseases (NASH, and NASH associated liver cancers); cancer gene therapy and experimental therapeutics for cancers signal transduction; apoptosis, cancer gene regulation
Targeted therapy; clinical trial; drug Safety profile; breast cancer/ (gastric)gastrointestinal cancer; prostate metastatic and treatment
Dr Stephen J. Ralph: Sole inventor on two full patents, and co-inventor on two additional provisional patent applications - 4 patents based on his research outputs covering cancer vaccines, improved immune adjuvants to enhance the potency of vaccines and design of novel anticancer drugs has meant that the research is well positioned now with secure Intellectual Property ready for commercialisation.. These patents will all become full national phase by the end of 2010. Show a continual history of major federal, state and local competitive grant funding success starting at Monash and continuing at Griffith University, as lead CIA on 2 NHMRC grants, a Queensland Cancer Council grant, and CIB on a QCC grant, ARC project grants, a prestigious National Breast Cancer Foundation, Kathleen Cunningham grant. Total State and Fed. grant funds in excess of $1million, excluding $300,000 in GURIP and GURG internal Griffith University grants for funding to purchase an ultrasound machine for use on small animals. Currently applying to ARC LIEF in a bid for a micro CT scanner as well as a light based imaging machine for small animals. Dr Ralph has successfully attracted large research investments from pharmaceutical companies and private investors repeatedly for his laboratory to develop cancer vaccines and novel cancer therapies with net worth of over $2.5 million over the last 10 years. After many presentations to CM Capital, Uniseed, Cancervax, Glycoz, Serono, Avastra, Biotech Capital, Starfish, GB investments and others including QLD State Govt, in late 2003, successfully secured funding from the pre-seed capital fund, SciVentures, to enable development of cancer vaccine formulation into phase I clinical trials and obtained SPIRT grant (equivalent of ARC Linkage grant). However, SciVentures withdrew support in 2004 and SPIRT grant had to be relinquished. In July 2004, in collaboration with Prof. Grant McArthur at the Peter MacCallum Cancer Research Institute in Melbourne, a grant of ~ $25,000 was obtained from Schering Plough Pty Ltd. to undertake a retrospective clinical study of archival melanoma patient responses to interferon therapy. This successfully showed that expression of two biomarkers in clinical samples provided excellent predictors of patient responses to interferon therapy and this represents a very significant advance in the use of interferons as a drug. Invited speaker at the EMBO meeting on Mitochondria and Cancer “MAC 09” in Prague in 2009 and chaired a session. As scientific director of Genvax Pty Ltd, involved in managing the research and development of cancer vaccines, having obtained ethics for a Therapeutics Goods Administration Australia registered Phase I clinical trial presently proceeding at the Princess Alexandra Hospital, Brisbane, since early 2009. Currently a consultant to Australian Botanical Biosciences Pty Ltd (now Active 98 Pty ltd) involved in developing Australian tea tree oil based products as anticancer drugs, now in clinical trial. Visiting Research Fellowship applied for and obtained for collaborator, Prof. Rafael Moreno-Sanchez, from Mexico in 2009 as an expert helping to identify target sites in the mitochondrial respiratory chain for the MITOCAN, alpha tocopheryl succinate. This collaboration has proved extremely successful.
Metastatic malignancy; relationships to the immune system and mechanisms for promoting metastasis; the relevance of hypoxia and galectin expression as a trigger for the process within the tumor micronenvironment;menaloma; lung metastasis; anticancer drug
Biological basis of hyperthermia in association with radiotherapy and chemotherapy; head and neck cancer; prostate cancer; breast cancer; image fusion in radiotherapy treatment planning ; nasopharyngeal cancer treatment; brain cancer
Palma Rocchi received her PhD in 2002 from the Medicine Faculty of Marseille evaluating the molecular mechanisms involved in the castration-resistant prostate cancer (CRPC). In her three years as post-doctoral fellow in the University of British Columbia Prostate Centre in Dr Gleave’s Lab. Palma Rocchi completed her formation by receiving advance training in targeting genes associated with CR and treatment resistance in PC. She developed a drug (OGX-427) using oligonucleotide antisens and siRNA approach able to significantly dose-dependent down-regulate Hsp27 protein expression level. OGX-427 has been patented and obtained an international license by the University of British Columbia and Oncogenex and clinical trials phase II is now in process in Canada and United States to evaluate the effect of OGX-427 in patients with PC and other solid tumors like breast, ovarian, bladder, prostate and lung cancer. She has now completed her post-doctoral fellowship and found a position as an independent senior investigator in PC translational research at the French National Institute for Health and Medical Research. She is now leading a research group on translational research to improve treatment resistance in PC. Her principal research interest is focused drug discovery for the treatment of CRPC.
Drug discovery for the treatment of castration-resistant prostate cancer; celltherapy metastatic prostate cancer
Dr. Rodriguez earned his BS in Microbiology and a MS in Immunology from the University of Antioquia. Then, he obtained his PhD from Louisiana State University and completed a post-doctoral fellowship in Tumor Immunology/Immunotherapy. His group in the Medical College of Georgia investigates the effect of myeloid-derived suppressor cells (MDSC) in tumor-induced anergy and the development of strategies to overcome immune suppression triggered by tumors.
Cancer Immunology, Inflammation
Dr. Antonio Rozzi is a graduated cum laude in 1998 at University of Rome “ Sapienza”. From November 1998 to November 2002: fellowship training in Medical Oncology at Experimental Medicine Department of University of Rome “Sapienza”. November 2002: Graduated cum Laude in Medical Oncology (II° School of Clinical Oncology of University of Rome “Sapienza”). From 1998 to 2002 actively involved in a regional home-care programme for terminally-ill cancer patients. From 2002 consultant oncologist at Clinical Oncology Unit of Istituto Neurotraumatologico Italiano of Grottaferrata (Rome). From 2010 this unit was chosen by European Society of Medical Oncology (ESMO) as designated center of Integrated Oncology and Palliative Care.
Medical treatment of solid tumors; supportive care chemotherapy-induced nausea and vomiting in glioblastoma lung cancer head and neck squamous cell cancer urothelial cancer; chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer; chemotherapy in patients with metastatic transitional cell carcinoma; chemotherapy with metastatic NSCLC
Dr. Domenico Rubello is Professor of Nuclear Medicine in Oncology and Positron Emission Tomography (PET) at the Post-graduate Radiotherapy and Oncology Medical School at Padova University and Nuclear Medicine in Radio-guided Surgery at the Post-graduate Surgery Medical School at Padova University. He is Head of the Nuclear Medicine Service, PET/CT Centre at Rovigo General Hospital in Veneto (Italy).He is Director of the Department of Imaging (Radiology, Medical Physics, Nuclear Medicine and PET/CT Centre) at Rovigo General Hospital in Veneto (Italy). He is/has been member of various scientific Societies (American Society of Nuclear Medicine-SNM, European Association of Nuclear Medicine-EANM, Italian Association of Nuclear Medicine-AIMN, Italian Study Group on Radioguided Surgery-GISCRIS and so forth). He has been Chair of the Parathyroid Study Group of the Italian Association of Nuclear Medicine-AIMN from 2000 to 2008. He is author of more than 1000 scientific papers, 349 of them cited in PubMed/MEDLINE (other 8 accepted full papers for publication will appear shortly in PubMed/MEDLINE) and 27 Textbooks or Chapters of Textbooks in Nuclear Medicine, Radio-guided surgery, PET and Oncology.
Nuclear medicine; radio-guided surgery; PET and oncology; endocrine tumours; thyroid tumours; adenoma; neuroendocrine tumours; metastatic thyroid tumours; neuro-oncology
Dr. Ruggiero received his medical degree from the Catholic University in Rome in 1992. He holds Board of Pediatrics in 1996 and Board of Pediatric Haematology and Oncology in 1998 at the Catholic University of Rome.
Dr. Ruggiero is currently an aggregate professor in the Department of Pediatrics at the Catholic University of Rome where he is responsible for teaching Pediatrics and Pediatric Hematology and Oncology. Carrying a regular patient load as consultant in pediatric hemato-oncology allows him to maintain his clinical skills and to promote improvements in safety and quality of healthcare.
Examples of activities include producing guidelines for prevention of healthcare associated treatments and improvements in basic safe medical practices.
His research interests focus on pediatric clinical trials, clinical pharmacology of antineoplastic drugs, pain therapy and pediatric drugs.
Clinical pharmacology; antineoplastic drugs; clinical trial; pediatric drugs
Chemotherapy and targeted therapies of solid tumors; therapy in breast/ovary and gastric cancer colon metastasia treatment; bone metastasis trreatment
Hematology; prostate and breast cancer; bone cancer
Dr. Saleh is a Consultant of Clinical Biochemistry and Ass. Professor of Cancer Biology at the Faculty of Medicine, Umm Al Qura University (UQU), Saudi Arabia. He previously worked at the Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University, Egypt.
Dr. Saleh is an Advisor for Vice Presidency for Business & Innovation at UQU and he has overall responsibility for international collaboration.
Dr Saleh’s technical expertise including state of the art cellular and molecular methods, such as qPCR; protein purification, western blot; Flow Cytometry and FACS; Protein Sequencing techniques; ELISA and CLIA. In addition to ICP-MS and HPLC.
Dr. Saleh is a member of American Association of Clinical Chemistry [AACC]; American Society for Biochemistry and Molecular Biology [ASBMB]; The Egyptian Society of Biochemistry and Molecular Biology; and The Egyptian Society for Tumor Markers Oncology.
Diagnostic oncology; prostate cancer; bladder cancer
Experimental pathology and oncology including GI and cancer related with infections; GI cancer; urothelial cancer and the association between schistosoma haematobium and bladder cancer
Breast cancer; prognostic and predictive factors in breast cancer; pathology and histology
Paediatric neuro-oncology; chemoresistance analysis of paediatric and adult CNS tumors and in vivo and in vitro studies on MDR at the BBB level; bladder cancer, prostate cancer; colon cancer; brain cancer; melanoma
Dr. Schiemann is the Goodman-Blum Professor in Cancer Research within the Case Comprehensive Cancer Center at Case Western Reserve University; he is also the Leader of the Breast Cancer Program in Development. He received his PhD in Pharmacology from the University of Washington in 1996, followed by Postdoctoral training in Cancer Biology in the laboratory of Dr. Harvey F. Lodish at the Whitehead Institute for Biomedical Research/MIT from 1997-2001. He began his independent research career as an Assistant Professor at the National Jewish Medical and Research Center (Denver, CO) in 2001, and later as an Associate Professor of Pharmacology at the University of Colorado-Denver Anschutz Medical Campus (Aurora, CO) in 2006. His current research efforts center on elucidating the molecular mechanisms of breast cancer metastasis and metastatic latency/dormancy, as well as on determining how these events impact the behaviors of cancer stem cells.
Breast cancer development and metastatic progression; metastatic latency and/or dormancy; EMT programs; cancer stem cells; short and long noncoding RNAs; integrins and mechanotransduction; signal transduction; TGF-β biology.
The role of neurotransmission in the development and progression of lung cancer and pancreatic cancer and the potential targeting of neurotransmitter receptor pathways for the prevention and therapy of these cancers
Professor Jalid Sehouli is currently Director of Department of Gynecology, Charité Campus Virchow-Klinikum and Head of Gynecological Cancer Center Charité in Berlin, Germany. He plays an active role in many key societies and is a Board Member of German Gynaecological Oncology Working Group (AGO) as well as a Chair of the Official Ovarian Cancer Guideline Commission of AGO. He is also an Official German Member of the Gynaecologic Cancer Intergroup (GCIG) and a founder member, board member and Secretary of the North-Eastern German Society of Gynaecological Oncology. Currently, he established the Pan Arabian Society for research in Gynecological Oncology (PARSGO) and is their president. He has published extensively in the area of gynaecological oncology including preclinical, phase I, phase II and phase III trials. His special interest is research on surgical and medical interventions in advanced gynecological malignancies with special focus on translational research and quality of life. Furthermore, he is the founder of the German Ovarian Cancer Foundation to increase the awareness about ovarian cancer.
Gynecology; ovarian cancer; gynaecologic cancer; anticancer drugs
Prof. Dr. Nedime Serakıncı was born in Nicosia in 1970. She completed her undergraduate biology degree in İstanbul University in 1992. She received her Master’s degree at Division of Internal Medicine, Çapa Faculty of Medicine, Istanbul University in 1993 and continued onto Faculty of Medicine with a special student status. She completed her first PhD at Department of Medical Biology and Genetics in Marmara University. Through her research on telomere-telomerase biology, cancer and stem cell biology, With the funding she received for various projects, she established ‘Stem cell and Genetic Therapy’ research program within the Institute of Human Genetics at Aarhus University.
Besides medical genetics, Prof. Serakıncı also works on and interested in mesechymal stem cell biology, cancer and telomere/telomerase biology. In 2003, she became an associate professor in the field of Medical genetics and received another associate professorship in her second field of interest, aging and stem cell genetics, in 2007. She received professorship in the fields of medical genetics and stem cell genetics in 2011.
Her research expertise is in telomerase-immortalized mesenchymal stem cells and their use in genetic therapy and development of tissue models for drug discovery.
Prof. Dr Serakıncı’s research program is focused on the molecular, cellular and developmental biology of the adult mesenchymal stem cell. The principle aim of the program is to develop strategic and technical approaches necessary to acquire an understanding of the mechanisms underlying stem cell self-renewal and differentiation processes. Ultimately the objective is to provide rational scientific foundations for the application of cell and gene based therapies to the treatment of human disease and injury.
mesenchymal stem cells; telomere/telomerase biology; Genetics and cancer diagnosis; leukemia
Lung cancer; breast cancer
Genetics aspects of cancers; acute myeloid leukaemia
Qiang Shen, MD, PhD, is an Assistant Professor in the Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences at the University of Texas M. D. Anderson Cancer Center. He earned his PhD in Cell Biology from The University of Texas Medical Branch at Galveston in 2001. Dr. Shen then did a postdoc with Dr. Powel Brown at Baylor College of Medicine, Lester and Sue Smith Breast Center till 2006 and was then promoted to Instructor in the Departments of Medicine and Cellular & Molecular Biology. Dr. Shen joined the Department of Clinical Cancer Prevention at M.D. Anderson Cancer Center in 2009. Dr. Shen’s current research focuses on elucidating the mechanisms by which normal pancreatic and mammary cells are malignantly transformed into cancer cells. He is interested in identifying novel targets for the prevention and treatment of pancreatic and breast cancer. More specifically, Dr. Shen studies the activation of transcription factors, kinases, and ion channels in normal and cancer cells; using molecular, cellular and transgenic approaches. In addition, Dr. Shen recently obtained an NIH/NCI K22 Award to conduct a study on the AP-1 transcription factor in breast cancer metastasis.
Pancreatic and breast cancer; medicine and cellular & molecular biology
Breast and endocrine surgery; medical oncology (breast cancer); biology of breast cancer
Dr. Siddiqui earned his BSc and MSc degrees in Biochemistry from the University of Karachi, in Karachi, Pakistan. He obtained his PhD from the Australian National University in Canberra, Australia. While obtaining his PhD, he investigated the metabolic basis of cancer cachexia under the supervision of Professor John F. Williams, who is famous for his pioneer research on the pentose phosphate pathway. Dr. Siddiqui served as a postdoctoral fellow at Massey University in Palmerton North, New Zealand in the laboratory of Dr. Stuart McCutcheon (currently Vice Chancellor of Auckland University in New Zealand). Dr. Siddiqui immigrated to America in 1989 and worked as a Howard Hughes fellowship at Vanderbilt University Medical Center in Nashville with Dr. John Exton. Dr. Siddiqui began his work as a researcher at Methodist Hospital in 1993 in the Bone Marrow Transplant Research Laboratory. He established his independent research laboratory in 1999 and is presently the Senior Investigator and Director of the Cellular Biochemistry Research Laboratory at the Methodist Research Institute. Dr. Siddiqui also has adjunct appointments in the Department of Biology, Indiana University-Purdue University and the Department of Medicine, Indiana University Medical School, Indianapolis. Dr. Siddiqui has received funding from the National Cancer Center (NIH), American Heart Association, Showalter Foundation, Abbott Pharmaceuticals, and Baxter Nutrition.
Kinase inhibitors; cancer biology; brain tumors and metastasis
Leukemia; nasopharynx cancer
Dr Sabrina Daniela da Silva DDS, MSc, PhD is an assistant professor at the Department of Otolaryngology – Head and Neck Surgery at McGill University and project director at the Lady Davis Institute for Medical Research - Segal Cancer Center. She obtained her DDS degree from University of Sao Paulo State, Brazil and her MSc and PhD in Pathology and Molecular Biology at University of Campinas (UNICAMP, Brazil). She carried out fundamental research to understand the mechanism of tumor progression including the establishment of orthotropic metastatic models using tissues samples from patients with head and neck cancer. In 2014, Dr. da Silva became an assistant professor at McGill, where she is now leading basic and translational research with a primary goal to improve prevention, early tumor detection, and discover alternative therapeutic approaches for patients with advanced disease.
Carcinogenesis, Cancer progression, Metastasis signaling, Preclinical and animal models, Genetic, Genomic and Epigenomic, Target and Drug Discovery
Dr. Ira-Ida Skvortsova studied medicine at the Altai State Medical University (Russia) from 1981-1987. She completed her oncology residency at the same University, as well as an ESMO research fellowship at Innsbruck Medical University (Austria). Since 2000, Dr. Skvortsova is a head of the Laboratory for Translational Research in Radiation Oncology (Dept. of Therapeutic Radiology and Oncology, Innsbruck Medical University).
Antonio Sommariva is Surgical Oncologist at the Surgical Oncology Unit of Istituto Oncologico Veneto where he is actively involved in the surgical care of cancer patients. He specialized in General Surgery at the University in Padova. He spent study periods at the following institutions (Jackson Memorial Hospital, Miami-USA, Royal Infirmary, Edinburgh-UK and MD Anderson Cancer Center, Houston-USA). He is member of European Society of Surgical Oncology-ESSO and the Italian Melanoma Intergroup-IMI. His clinical and research activity is mainly directed in melanoma, soft tissue sarcomas and peritoneal carcinomatosis. Currently he leads international clinical research projects on minimally invasive surgery techniques and quality control in surgical oncology. He is collaborator of the International Melanoma Database and Discovery Platform (IMDDP) and is involved as contributing data center for the next AJCC 8th edition melanoma staging system.
Melanoma and sarcoma; gastrointestinal oncology gastric cancer
Prof. Paul De Souza served as Chairman of Medical Advisory Board at Novogen Limited since August 7, 2013. Prof. De Souza is the Foundation Professor of Medical Oncology at the University of Western Sydney, Director of the Translational Cancer Research Unit of The Ingham Institute of Medical Research, Conjoint Professor in the Faculty of Medicine of the University of NSW, and Director of the Department of Medical Oncology at Liverpool Hospital.
Preclinical investigation of novel compounds; synergistic combinations of therapies; targeted therapies; signal transduction; cell biology; pharmacokinetics; pharmacodynamics; clinical pharmacology; translational research; and early Phase clinical trials.lymphoma; prostate cancer; bone metastases; ovarian cancer; lung cancer; breasr cancer; renal cancer; treatment with metastatic renal cell carcinoma; bone cancer prostate cancer
Melanoma; lung cancer; breast cancer
Melanoma; cancer immunology
Lung metastases; lymph node metastases; lung cancer
Melanoma.; glioblastoma; cervical cancer
Dr. Giorgio Treglia is currently a research scientist and nuclear medicine physician at the Oncology Institute of Southern Switzerland in Bellinzona and Lugano (Switzerland). He obtained his M.D. degree in 2003 and his post-graduate degree in nuclear medicine in 2007 from the Catholic University of Rome (Italy). Previous work experience: nuclear medicine physician at the Major Hospital of Bologna (Italy) from 2008 to 2009 and nuclear medicine physician at the Gemelli University Hospital of Rome (Italy) from 2010 to 2012. He is author and co-author of 77 full-text scientific articles cited in Pubmed or Scopus database and 6 book chapters. He is also winner of several international awards about nuclear medicine.
Evidence-based medicine; meta-analyses and systematic reviews; PET imaging; imaging biomarkers; thyroid carcinoma; prostate cancer; gastric cancers
Giovanni Tuccari was born in Messina 9 August 1955. He achieved the degree in Medicine and Surgery (points 110/110 cum laude) at the University of Pisa (31 October 1979). - Specialization in Anatomic Pathology (points 50/50 cum laude) at the University of Messina (23 July 1983). Associate professor of Pathology at University of Messina (25 May 1987). Full professor of Pathology at the University of Messina (14 March 2000). Vice-Chancellor at the University of Messina for Health's Questions (2013, until now). Reviewer and component of the scientific board of many journals. Member of many scientific Societies.
Cancer biology; colorectal cancer; cancer biomarkers; cancer diagnostics; cell Signaling
She is the head of the Glycoimmunology Research Group. She presently coordinates several multidisciplinary national and international projects in Glycosciences, involving clinical teams, as well as Biotech and Pharma companies and patient associations. Her focus is on Glycobiology, Oncobiology and Immunology projects with impact on cancer, infection and rare diseases. She is an Assistant Professor and director of the Congenital disorders of Glycosylation - Professionals and Patient Associations International Network(CDG & Allies - PPAIN).
Glycan alterations in cancer cells, immunotherapies, dendritic cell-based vaccines, antibodies, rare diseases
Mesenchymal stem cells; breast cancer; EGF signal pathway
Prof. Zhou Wang is the Professor and UPMC Chair in Urological Research, Shadyside Medical Center, university of Pittsburgh. Prof. Wang’s lab is interested in the mechanism of androgen action and the roles of androgens in benign and cancerous prostate growth. The long-term objective of his research is to identify new targets for the treatment and prevention of prostate cancer and benign prostatic hyperplasia (BPH).
One area of research is to determine the role of androgen-responsive genes in the prostate. Prof. Wang’s lab recently showed that one of the androgen-responsive gene, U19/Eaf2, is a tumor suppressor. U19/Eaf2 downregulation and loss of heterozygosity were observed in more than 80% of advanced human prostate cancer specimens examined, indicating that Eaf2 likely blocks prostate cancer progression. Overexpression of Eaf2 induced apoptosis of prostate cancer cell lines, both in vitro and in vivo, while Eaf2 gene knockout in mice resulted in tumors in multiple tissues. These findings demonstrate that Eaf2 indeed functions as a tumor suppressor. His current research focuses on U19/Eaf2-binding partners and Eaf2-downstream genes to better understand U19/Eaf2 function in prostate carcinogenesis and to elucidate the mechanisms by which androgens can modulate prostate cancer progression.
Receptor Pharmacology; Drug Discovery; Cancer Pharmacology; Signal Transduction
Chia-Jui Weng is a professor/Ph.D. served in Department of Living Services Industry, Tainan University of Technology, Taiwan. He received his PhD at Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan in 2008. He was the Lead Guest Editor of BioMed Research International and Guest Editor of Evidence-Based Complementary and Alternative Medicine (eCAM) Journal. He also to be the Editorial Board Member of Journal of Turgut Ozal Medical Center (ISSN: 1300-1744), Journal of Tumor (ISSN 1819-6187), and Journal of Hepatocellular Carcinoma (ISSN: 2253-5969).
Hepatocarcinoma, Natural bioactives and phytochemicals, cancer invasion and metastasis, single nucleotide polymorphism
Katarina Wolf obtained her PhD in cell biology and biochemistry at the University of Wuerzburg, Germany (2003). After working as a postdoc at the University of Wuerzburg she holds an assistant professor position at the Department of Cell Biology at the Radboud University Medical Center in Nijmegen, The Netherlands. Her research focuses on proteolytic and non-proteolytic mechanisms, including nuclear mechanics, of tumor invasion.
Tumor cell invasion, cell migration modes and plasticity, MMPs, ECM, tumor imaging, nuclear deformability, nuclear envelope rupture.
Multi-disciplinary team treatment of gastric and colorectal cancer; laparoscopic surgery of gastric cancer and colorectal cancer
Prof. Xie focuses on mechanisms underlying human disease, with the goal of improving patient care and outcomes. During graduate and postdoctoral training, he gained tremendous experience in molecular biology and expertise in utilizing various in vivo animal models. he also contributed to fields of study that resulted in frequently-cited publications, i.e., the novel role of zinc-finger protein and the ATM gene in cell fate determination and cell cycle checkpoints, respectively. His work with human colon cancer cells led to the seminal observation that muscarinic receptor activation stimulates expression of selected matrix metalloproteinases (i.e., MMP1, MMP7 and MMP10). Work supported by his NIH K08 award is focused on elucidating the role and mechanisms of MMP gene expression and activation in promoting colon neoplasia.
The role of matrix metalloproteinases in mediating farnesoid X receptor- and muscarinic receptor-dependent intestinal epithelial cell proliferation and colon neoplasia; esophageal motility disorders and colorectal cancer; internal medicine and gastroenterology; gastric cancer
Notch signaling pathway in mammary development and breast cancer; notch activation in lung development and lung cancer; fringe proteins
Dr. Ren Xu is an Associated Professor at the Markey Cancer Center, University of Kentucky. Research in his group focuses on the biological function and regulation of ECM microenvironment in normal tissue and cancer development. His recent findings reveal the crucial function of cancer-cell derived-ECM in breast cancer progression.
Dr. Oksana Yaskiv is assistant professor of pathology at Hofstra North Shore LIJ School of Medicine. She has the American Board of Pathology certification in anatomic and clinical pathology. Her area of clinical expertise includes genitourinary pathology.
Dr. Yaskiv received her medical degree from Danylo Halytsky Lviv State Medical Institute, Ukraine and completed her pathology residency training at North Shore LIJ Health System. She subsequently, completed surgical pathology fellowships at Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis MO and genitourinary pathology fellowship at Cleveland Clinic Foundation, Cleveland OH.
Her research interests are focused on characterization of prostate cancer using imaging and molecular techniques as well as molecular characterization of bladder cancer. Additional interests include male infertility diagnosis and epidemiological study of renal cancers. She serves on several editorial boards of pathology journals.
Cancer signaling; in vivo tumor animal model(mouse); development of anticancer drugs; melanoma; lung cancer; colon cancer; breast cancer; bladder cancer; cervical cancer
Lugang Yu is Professor of Glyco-Oncology and Deputy Director of Centre for Glycobiology. He is a member of the British Association for Cancer Research, European Association for Cancer Research, Biochemical Society, and Society of Glycobiology. He serves on the editorial boards of several cancer and glycobiology journals.
Functional significance and therapeutic potential of cellular glycosylation and carbohydrate-binding proteins (e.g. the galactoside-binding galectins) in cancer progression and metastasis; gastric cancer
Dr. Yoshihito Yokoyama is presently working as a professor in Department of Obstetrics and Gynecology at Hirosaki University Graduate School of Medicine, Japan. He holds a membership in various international Gynecology societies. He is an Editorial board member in various international journals. His areas of interest includes Angiogenesis, Apoptosis, Ovarian carcinogenesis, VEGF, Peroxisome proliferator-activated receptors.
Angiogenesis; apoptosis; ovarian carcinogenesis; VEGF; peroxisome proliferator-activated receptors; ovarian cancer; radiotherapy cervical cancer; liver cancer;renal cancer; intracardiac metastasis and treatment
Dr. Jin-Zhang Zeng received his B.S. (1989), M.S. (1995) and Ph.D. (1998) at First Military Medical University (Guangzhou, China). He continued his academic research at Second Military Medical University as a postdoctoral fellow, assistant professor and associate professor from 1998 through 2005 (Shanghai, China). After that, he worked as an associate professor (2005-2006) at Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and as a visiting scholar (2006-2007) at Sanford-Burnham Medical Research Institute (CA, La Jolla). In 2007, Dr. Zeng moved to Xiamen University (XMU) to set up his own laboratory as a Professor and acting director of Cancer Center at Institutes for Biomedical Research. From 2011 till now, Dr. Zeng is Professor and Deputy Dean of School of Pharmaceutical Sciences (XMU). He has published papers on top journals, including Cancer Res, Cancer Cell, Oncogene, FASEB J, PLoS ONE, Carcinogenesis, J Biol Chem, Anal Chem and Expert Opin Ther Targets. He is also a co-inventor of eight issued patents and a peer reviewer of Cancer Res, Carcinogenesis, Biochem Pharm, BMC Cancer, Genomics Proteomics and Bioinformatics, and Acta Pharmacol Sin. In recent years, he was awarded for more than ten research grants, including funding from National 863 Project, National Natural Science Foundation of China, NSFC/RGC project, Science and Technology Project of Fujian Province, Natural Science Foundation of Fujian Province, joint R&D projects.
Tumor biology; colon cancer; liver cancer
Anticancer drugs; adenomas; pituitary adenomas
Prof. Zhou is an Associate Dean of International Research, and Chair of the Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, Florida. Professor Zhou completed his clinical medical training in China in 1989 and obtained his PhD in 2001 from the School of Medicine, the University of Auckland, New Zealand. Since 2002, Dr Zhou has served as a faculty member for the National University of Singapore, Queensland University of Technology, Australia, and RMIT University, Australia.
Drug discovery; systems pharmacology; systems pharmacology; drug metabolism & drug transport; pharmacokinetics/pharmacometrics; pharmacogenomics, nanomedicine and Chinese medicine; liver cancer
Prof. Bo Zhu is the Director and Professor at the Institute of Cancer, Xinqiao Hospital, Third Military Medical University. Dr. Zhu received his bachelor and doctoral degrees at the Third Military Medical University. He was trained as a postdoctoral at Queen Mary’s School of Medicine, London, UK. He is also a Chief Physician in Oncology. Dr. Zhu’s basic research and translational medical research mainly focuses on lung cancer immunology and immunotherapy. His work has been published on several renowned journals, such as J Exp Med, J Clin Invest, Clin Cancer Res, Stem Cells, Oncogene, Oncotarget, and so on. He has been actively involved in more than five clinical trials for non-small-cell lung carcinoma as center PI during last three years.
Tumor microenvironment, Tumor immunology and Immunotherapy